Patiromer is a non-absorbable potassium binding polymer indicated for the treatment of hyperkalemia. Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.
- Mechanism
- Curator reviewed · 1 reference
Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. It increases fecal potassium excretion by binding to potassium in the lumen of the gastrointestinal tract, reducing the concentration of free potassium in the gastrointestinal lumen and, ultimately, in the serum.
- Primary indication
- Patiromer is indicated for the treatment of hyperkalemia.Curator reviewed · 1 structured indication
- First approval
- Canada, 2018 · United States, 2015 · European Union, 2020
- Also known as
- Patiromer FOS
- Code names
- RLY5016 · ZG-801
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which other approved drugs treat the same conditions as Patiromer, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account